GlassScriptPhysician profile
Vin T Dang
NPI 1053503979
$283,549.71
in general payments reported to CMS, 2019-2025
30 companies · $50K in 2025
The $50K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $16K · 2021: $14K · 2022: $54K · 2023: $48K · 2024: $62K · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $53K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44K · Consulting Fee: $30K · Travel and Lodging: $26K · Food and Beverage: $7,990 · Education: $9.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $53,050.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,939.11 |
| Consulting Fee | $29,925.00 |
| Travel and Lodging | $25,519.20 |
| Food and Beverage | $7,990.32 |
| Education | $9.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $73,782.19 | 2022-2025 | Miebo, Xiidra, Blink Nutritears |
| Sun Pharmaceutical Industries INC. | $41,732.42 | 2019-2025 | Cequa, Xelpros |
| Tarsus Pharmaceuticals, INC. | $25,772.02 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $23,267.82 | 2019-2024 | Omni Surgical System, Tearcare System |
| Allergan, INC. | $18,369.41 | 2021-2022 | |
| Oyster Point Pharma, INC. | $17,627.56 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Abbvie INC. | $16,668.32 | 2022-2025 | Vuity, Lumigan, Alphagan P |
| Novartis Pharmaceuticals Corporation | $12,094.61 | 2019-2023 | |
| Biotissue Holdings INC. | $10,294.38 | 2019-2025 | |
| Dompe US, INC. | $8,828.69 | 2019-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $6,856.77 | 2019-2022 | |
| Carl Zeiss Meditec, INC. | $6,052.18 | 2019-2024 | Cirrus Hd-Oct, Iolmaster 700, Humphrey Hfa |
| Harrow Eye, LLC | $3,918.42 | 2024-2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $3,863.96 | 2019-2023 | Flarex |
| Shire North American Group INC | $3,812.73 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $2,583.74 | 2019-2021 | |
| Horizon Therapeutics Plc | $2,260.89 | 2020-2023 | Tepezza |
| Alcon Vision LLC | $1,340.34 | 2019-2025 | Rocklatan |
| Thea Pharma INC. | $1,168.99 | 2022-2024 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $725.73 | 2019-2021 | |
| Glaukos Corporation | $612.83 | 2021 | |
| Ocular Therapeutix, INC. | $570.31 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $558.84 | 2024-2025 | Cirrus Hd-Oct, Atlas 500, Clarus |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $283.54 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $151.55 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $140.14 | 2024 | Acthar |
| Coopervision INC. | $95.30 | 2019-2021 | |
| Amgen INC. | $50.80 | 2024-2025 | Tepezza |
| Quidel Corporation | $33.17 | 2019 | |
| Genzyme Corporation | $32.06 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vin Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.